We are testing AMG 193 combined with other therapies for patients with advanced gastrointestinal, biliary tract, or pancreatic cancers that have a specific genetic deletion. The goal is to see if this combination improves treatment outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Biliary and pancreatic cancers are types of cancer that affect the bile ducts and pancreas, respectively. These cancers can be aggressive and may spread to other parts of the body, often leading to symptoms like jaundice, abdominal pain, weight loss, and digestive issues.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
